Publication of the activity report and financial information for the first half-year (April – Sept. 2019)
3 December 2019
FOR ANY FURTHER INFORMATION,
PLEASE CONTACT:
communication@medincell.com
Our news
Bringing you the latest!
All news
MedinCell receives $19 million grant for its mdc-WWM program
28 November 2019
MedinCell announces that mdc-CWM progresses as planned
27 September 2019
The MedinCell General Meeting votes to include the “Raison d’être” of the Company in its articles of association
10 September 2019
MedinCell receives a new grant to develop a best-in-class long-acting injectable product for HIV PrEP
5 September 2019
MedinCell partners to address the untapped financial potential in Animal Health
28 August 2019
LAI antipsychotic using MedinCell’s technology receives FDA IND clearance to initiate clinical activities
26 August 2019
MedinCell receives 7,5 M€ from the European Bank of Investment (EIB)
23 July 2019
Press
Communication leader
MedinCell
David Heuzé
david.heuze@medincell.com
+33 (0)6 83 25 21 86
Media
NewCap
Nicolas Merigeau
medincell@newcap.eu
+33 (0)1 44 71 94 94
Investors
Investor Relations
NewCap
Louis-Victor Delouvrier /
Alexia Faure
medincell@newcap.eu
+33 (0)1 44 71 94 94